Maravai LifeSciences Holdings, Inc. (MRVI) Balance Sheet
MRVI balance sheet, 2025
December 31, 2025 · U.S. dollars$770.6M assets = $397.9M liabilities + $372.7M equity
Both columns are drawn to the same scale: what MRVI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
MRVI financial health
Descriptive bands, not a rating. Fiscal 2025.
MRVI balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $539.7M2018 | $770.6M2025 | +5.2%/yr | |
| Total liabilities | $391.7M2018 | $397.9M2025 | +0.2%/yr | |
| Shareholders’ equity | $144.4M2018 | $212.4M2025 | +5.7%/yr | |
| Cash & short-term investments | $21.9M2018 | $216.9M2025 | +38.8%/yr | |
| Total debt | $339.9M2018 | $35.6M2025 | −27.6%/yr | |
| Net cash (debt) | −$318.0M2018 | $181.3M2025 | +$499.3M | |
| Working capital | $17.9M2018 | $251.3M2025 | +$233.5M | |
| Book value per share | $1.622018 | $1.462025 | −1.5%/yr | |
| Current ratio | 1.502018 | 6.602025 | +5.10 | |
| Debt / equity | 2.352018 | 0.172025 | −2.19 | |
| Shares outstanding | 89.0M2018 | 145.1M2025 | +7.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
MRVI assets
MRVI liabilities and equity
MRVI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
MRVI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $216.9M | $322.4M | $575.0M | $632.1M | $551.3M | $236.2M | $24.7M | $21.9M |
| Cash & equivalents | $216.9M | $322.4M | $575.0M | $632.1M | $551.3M | $236.2M | $24.7M | $21.9M |
| Receivables | $25.5M | $38.5M | $55.7M | $146.8M | $117.5M | $51.0M | $18.0M | $16.0M |
| Inventory | $40.5M | $50.1M | $51.4M | $43.2M | $51.6M | $33.3M | $14.2M | $14.3M |
| Other current assets | $13.4M | $18.1M | $17.8M | $25.8M | $19.7M | $11.1M | $3.6M | $1.6M |
| Total current assets | $296.3M | $429.1M | $699.9M | $847.9M | $740.0M | $331.6M | $60.6M | $53.8M |
| Property, plant & equipment (net) | $1.2M | $217.0M | $222.6M | $116.6M | $95.4M | $101.3M | $94.3M | $42.6M |
| Goodwill & intangible assets | $281.0M | $354.8M | $547.0M | $500.3M | $270.3M | $401.9M | $422.1M | $442.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $192.1M | $7.2M | $17.9M | $817.5M | $812.5M | $435.9M | $805,000 | $894,000 |
| Total assets | $770.6M | $1.01B | $1.49B | $2.28B | $1.92B | $1.27B | $577.8M | $539.7M |
| Liabilities | ||||||||
| Accounts payable | $2.9M | $12.0M | $10.7M | $6.0M | $8.2M | $3.0M | $7.5M | $3.6M |
| Short-term debt | $5.4M | $13.7M | $12.9M | $11.7M | $9.7M | $6.0M | $2.5M | $2.5M |
| Deferred revenue | — | $3.3M | $3.4M | $3.1M | $12.6M | $78.1M | $841,000 | $1.1M |
| Total current liabilities | $44.9M | $57.0M | $87.5M | $110.1M | $93.8M | $130.8M | $29.6M | $35.9M |
| Long-term debt | $286.3M | $290.5M | $518.7M | $522.0M | $524.6M | $528.6M | $334.8M | $335.6M |
| Lease obligations | $72.9M | $80.8M | $86.8M | $57.8M | $3.7M | $56.2M | $52.9M | $1.8M |
| Other long-term liabilities | $66.6M | $83.6M | $91.4M | $744.9M | $754.5M | $456.6M | $68.8M | $20.2M |
| Total liabilities | $397.9M | $431.0M | $697.6M | $1.38B | $1.37B | $1.12B | $433.2M | $391.7M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $2.6M | $2.5M | $2.5M | $2.6M | $2.6M | $2.6M | $183.9M | $182.8M |
| Retained earnings (deficit) | $10.1M | $140.9M | $285.7M | $404.8M | $184.6M | $854,000 | −$42.4M | −$38.2M |
| Accumulated other comprehensive income | $524,000 | — | — | $0 | — | −$44,000 | −$133,000 | −$167,000 |
| Minority interest | $160.3M | $251.9M | $373.1M | $360.0M | $229.9M | — | — | — |
| Total shareholders' equity | $212.4M | $325.3M | $416.8M | $545.2M | $315.5M | $88.5M | $141.4M | $144.4M |
| Key figures | ||||||||
| Total debt | $35.6M | $376.7M | $611.0M | $585.3M | $575.2M | $590.8M | $390.2M | $339.9M |
| Net cash (debt) | $181.3M | −$54.3M | −$36.0M | $46.9M | −$23.9M | −$354.6M | −$365.5M | −$318.0M |
| Working capital | $251.3M | $372.2M | $612.4M | $737.8M | $646.3M | $200.8M | $31.0M | $17.9M |
| Tangible book value | −$68.6M | −$29.5M | −$130.3M | $44.9M | $45.2M | −$313.4M | −$280.7M | −$298.0M |
| Book value per share | $1.46 | $2.36 | $3.16 | $4.14 | $2.59 | $0.92 | $1.46 | $1.62 |
| Shares outstanding | 145.1M | 137.9M | 131.9M | 131.7M | 122.0M | 96.6M | 96.6M | 89.0M |
| Current ratio | 6.60 | 7.53 | 8.00 | 7.70 | 7.89 | 2.54 | 2.05 | 1.50 |
| Quick ratio | 5.40 | 6.34 | 7.21 | 7.07 | 7.13 | 2.20 | 1.45 | 1.05 |
| Debt / equity | 0.17 | 1.16 | 1.47 | 1.07 | 1.82 | 6.67 | 2.76 | 2.35 |
| Equity / assets | 27.6% | 32.3% | 28.0% | 23.9% | 16.4% | 7.0% | 24.5% | 26.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $70.1M | $165.9M | $216.9M | $243.6M | $269.9M | $285.1M | $322.4M | $578.2M | $573.2M | $561.7M | $575.0M | $579.6M |
| Cash & equivalents | $70.1M | $165.9M | $216.9M | $243.6M | $269.9M | $285.1M | $322.4M | $578.2M | $573.2M | $561.7M | $575.0M | $579.6M |
| Short-term investments | — | — | — | — | — | — | — | — | $6.6M | — | — | — |
| Receivables | $31.1M | $33.4M | $25.5M | $22.5M | $27.9M | $28.5M | $38.5M | $28.9M | $39.3M | $39.5M | $55.7M | $49.2M |
| Inventory | $41.2M | $40.5M | $40.5M | $45.3M | $46.7M | $49.8M | $50.1M | $50.4M | $49.3M | $49.8M | $51.4M | $49.1M |
| Other current assets | $13.2M | $11.9M | $13.4M | $14.4M | $15.3M | $13.0M | $18.1M | $21.7M | $23.6M | $16.8M | $17.8M | $22.9M |
| Total current assets | $155.7M | $251.7M | $296.3M | $325.9M | $359.8M | $376.3M | $429.1M | $679.1M | $685.4M | $667.9M | $699.9M | $700.9M |
| Property, plant & equipment (net) | $142.4M | $146.9M | $1.2M | $158.6M | $162.7M | $166.4M | $217.0M | $164.6M | $165.5M | $161.6M | $222.6M | $216.4M |
| Goodwill & intangible assets | $267.8M | $274.3M | $281.0M | $315.3M | $322.5M | $359.5M | $354.8M | $373.6M | $533.3M | $540.1M | $547.0M | $553.9M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $37.9M | $40.2M | $192.1M | $49.4M | $52.0M | $57.6M | $7.2M | $60.9M | $63.5M | $75.0M | $17.9M | $796.4M |
| Total assets | $603.7M | $713.2M | $770.6M | $849.2M | $897.0M | $959.8M | $1.01B | $1.28B | $1.45B | $1.44B | $1.49B | $2.27B |
| Liabilities | ||||||||||||
| Accounts payable | $7.1M | $8.5M | $2.9M | $8.0M | $11.5M | $9.5M | $12.0M | $9.5M | $12.5M | $8.2M | $10.7M | $9.4M |
| Short-term debt | $1.1M | $5.4M | $5.4M | $5.4M | $6.3M | $6.3M | $13.7M | $13.5M | $13.3M | $13.1M | $12.9M | $13.1M |
| Deferred revenue | — | $3.2M | — | — | $1.6M | $2.8M | $3.3M | $2.9M | $3.5M | $4.2M | $3.4M | $2.6M |
| Total current liabilities | $38.4M | $42.6M | $44.9M | $61.6M | $69.7M | $63.2M | $57.0M | $63.2M | $68.6M | $59.0M | $87.5M | $78.3M |
| Long-term debt | $146.0M | $235.6M | $286.3M | $287.4M | $288.4M | $289.5M | $290.5M | $516.3M | $517.1M | $517.9M | $518.7M | $519.5M |
| Lease obligations | $29.6M | $29.9M | $72.9M | $75.1M | $69.7M | $75.7M | $80.8M | $39.4M | $39.4M | $39.4M | $86.8M | $89.7M |
| Other long-term liabilities | $63.8M | $65.9M | $66.6M | $68.4M | $70.9M | $76.8M | $83.6M | $85.6M | $85.6M | $90.3M | $91.4M | $777.5M |
| Total liabilities | $248.2M | $344.1M | $397.9M | $417.3M | $429.0M | $429.5M | $431.0M | $665.1M | $671.2M | $667.3M | $697.6M | $1.38B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.5M | $2.5M | $2.5M | $2.5M | $2.5M | $2.5M | $2.5M |
| Retained earnings (deficit) | −$6.0M | $6.4M | $10.1M | $45.8M | $71.4M | $110.9M | $140.9M | $167.0M | $266.1M | $273.7M | $285.7M | $391.7M |
| Accumulated other comprehensive income | $459,000 | $466,000 | $524,000 | $579,000 | $574,000 | $324,000 | — | $0 | — | — | — | — |
| Minority interest | $151.0M | $157.5M | $160.3M | $186.4M | $202.1M | — | — | — | — | — | — | — |
| Total shareholders' equity | $204.6M | $211.6M | $212.4M | $245.4M | $265.9M | $300.6M | $325.3M | $345.1M | $436.9M | $410.7M | $416.8M | $519.3M |
| Key figures | ||||||||||||
| Total debt | $176.7M | $270.9M | $35.6M | $35.8M | $363.6M | $326.7M | $376.7M | $561.1M | $561.9M | $562.7M | $611.0M | $614.7M |
| Net cash (debt) | −$106.6M | −$105.0M | $181.3M | $207.7M | −$93.7M | −$41.6M | −$54.3M | $17.1M | $11.3M | −$998,000 | −$36.0M | −$35.1M |
| Working capital | $117.2M | $209.1M | $251.3M | $264.3M | $290.1M | $313.1M | $372.2M | $615.9M | $616.8M | $608.9M | $612.4M | $622.6M |
| Tangible book value | −$63.2M | −$62.8M | −$68.6M | −$69.9M | −$56.6M | −$58.8M | −$29.5M | −$28.5M | −$96.3M | −$129.5M | −$130.3M | −$34.6M |
| Book value per share | $1.38 | $1.44 | $1.46 | $1.70 | $1.84 | $2.10 | $2.33 | $2.44 | $3.22 | $3.10 | $3.15 | $3.94 |
| Shares outstanding | 148.0M | 146.4M | 145.1M | 144.7M | 144.2M | 143.4M | 139.7M | 141.6M | 135.8M | 132.3M | 132.1M | 131.9M |
| Current ratio | 4.05 | 5.91 | 6.60 | 5.29 | 5.16 | 5.96 | 7.53 | 10.74 | 10.00 | 11.32 | 8.00 | 8.96 |
| Quick ratio | 2.63 | 4.68 | 5.40 | 4.32 | 4.27 | 4.96 | 6.34 | 9.60 | 8.93 | 10.19 | 7.21 | 8.04 |
| Debt / equity | 0.86 | 1.28 | 0.17 | 0.15 | 1.37 | 1.09 | 1.16 | 1.63 | 1.29 | 1.37 | 1.47 | 1.18 |
| Equity / assets | 33.9% | 29.7% | 27.6% | 28.9% | 29.6% | 31.3% | 32.3% | 27.0% | 30.2% | 28.4% | 28.0% | 22.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
MRVI financial position
At the end of fiscal 2025 (December 31, 2025), Maravai LifeSciences had total assets of $770.6 million (down 23.6% from a year earlier), total liabilities of $397.9 million and shareholders' equity of $212.4 million. It held $216.9 million in cash and short-term investments against $35.6 million of debt, a net cash position of $181.3 million. Its current ratio was 6.60. In the latest quarter (ended June 30, 2026) total assets were $603.7 million and equity $204.6 million.
Related: MRVI income statement, MRVI cash flow statement, MRVI key metrics. See the MRVI stock overview for the latest quote and news.
MRVI balance sheet FAQ
What are Maravai LifeSciences's total assets?
Maravai LifeSciences reported total assets of $770.6 million at the end of fiscal 2025 (December 31, 2025), compared with $1.0 billion a year earlier.
How much debt does Maravai LifeSciences have?
Maravai LifeSciences had $35.6 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.17.
How much cash does Maravai LifeSciences have?
Maravai LifeSciences held $216.9 million in cash and short-term investments at the end of fiscal 2025; with $35.6 million of debt that is net cash of $181.3 million.
What is Maravai LifeSciences's book value?
Maravai LifeSciences's shareholders' equity (book value) was $212.4 million at the end of fiscal 2025, or $1.46 per share.
What is Maravai LifeSciences's current ratio?
Maravai LifeSciences had current assets of $296.3 million and current liabilities of $44.9 million, a current ratio of 6.60 (it can cover its short-term obligations).
How much goodwill does Maravai LifeSciences have?
Maravai LifeSciences carried $281.0 million of goodwill and intangible assets, 36.5% of total assets, at the end of fiscal 2025.